Recent Progress Towards Vaccines and Antibody-based Therapies Against Alzheimer's Disease

被引：4

作者：

Ji, Wenbo ^{[1
,2
]}

Gong, Baofeng ^{[1
]}

Jin, Hong ^{[3
]}

Chen, Xiaohan ^{[1
]}

Li, Peng ^{[1
]}

Cheng, Wenbin ^{[1
]}

Zhao, Yuchen ^{[1
]}

He, Bin ^{[1
]}

Zhuang, Jianhua ^{[1
]}

Gao, Jie ^{[2
]}

Yin, You ^{[1
]}

机构：

[1] Navy Med Univ, Changzheng Hosp, Dept Neurol, Shanghai 200003, Peoples R China

[2] Shanghai Univ, Inst Translat Med, Shanghai 200444, Peoples R China

[3] Hongqi Hosp, Mudanjiang Med Coll, Dept Lab Med, Mudanjiang 157011, Peoples R China

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2021年 / 21卷 / 19期

基金：

中国国家自然科学基金;

关键词：

Alzheimer's disease; therapeutic vaccine; amyloid; tau; immunotherapy; targe drugs; AMYLOID CASCADE HYPOTHESIS; MOUSE MODEL; PASSIVE-IMMUNIZATION; THERAPEUTIC STRATEGIES; BETA OLIGOMERS; TAU PATHOLOGY; A-BETA; IMMUNOTHERAPY; SOLANEZUMAB; MODERATE;

D O I：

10.2174/1389557521666210805110920

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Alzheimer's disease (AD), one of the progressive neurodegenerative disorders, is characterized by clinical features such as memory loss, acquired skill loss, apraxia, and interpersonal and social communication disorders. The AD hallmarks at the neuropathological level include intracellular neurofibrillary tangles constituted by the hyperphosphorylated tau protein as well as the senile extracellular plaques dominated by the amyloid-beta (A beta) deposits. At present, AD treatment that mainly targeted towards improving symptoms and effective drugs to delay or stop disease progression is lacking. Vaccines and antibody-based therapies are a type of natural, synthetic, and gene recombinant biological product that treat or prevent disease progression by stimulating specific or non-specific immune responses. Compared with traditional targeted drugs, vaccines and antibodybased therapies have better safety and effectiveness and can even maintain the expression and stability of A beta and Tau proteins in patients for a long time. Logically, vaccines and antibody-based therapies are somewhat different from traditional drugs because these drugs can achieve the therapeutic effect of AD by activating immune cells and regulating the immune system of patients themselves, thereby clearing disease-related proteins and long-term survival. Complete cure is also observed in some patients after receiving the immunotherapy. Currently available vaccines and antibody-based therapies mainly target A beta and phosphorylated tau proteins. There are 44 vaccines and antibodybased therapies for AD, among which nine drugs are discontinued, three drugs are inactive, eleven drugs are in clinical phase 1, twelve drugs are in clinical phase 2, and seven drugs are in clinical phase 3. Currently, no vaccines and antibody-based therapies have been approved for AD treatment. In this paper, we review and analyse the research progress of vaccines and antibody-based therapies that are used to treat AD.

引用

页码：3062 / 3072

页数：11

共 72 条

[1] An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ [J].

Adolfsson, Oskar ;

Pihlgren, Maria ;

Toni, Nicolas ;

Varisco, Yvan ;

Buccarello, Anna Lucia ;

Antoniello, Katia ;

Lohmann, Sophie ;

Piorkowska, Kasia ;

Gafner, Valerie ;

Atwal, Jasvinder K. ;

Maloney, Janice ;

Chen, Mark ;

Gogineni, Alvin ;

Weimer, Robby M. ;

Mortensen, Deborah L. ;

Friesenhahn, Michel ;

Ho, Carole ;

Paul, Robert ;

Pfeifer, Andrea ;

Muhs, Andreas ;

Watts, Ryan J. .

JOURNAL OF NEUROSCIENCE, 2012, 32 (28) :9677-9689

[2] A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease [J].

Agadjanyan, Michael G. ;

Petrovsky, Nikolai ;

Ghochikyan, Anahit .

ALZHEIMERS & DEMENTIA, 2015, 11 (10) :1246-1259

[3] The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers [J].

Ashton, N. J. ;

Leuzy, A. ;

Karikari, T. K. ;

Mattsson-Carlgren, N. ;

Dodich, A. ;

Boccardi, M. ;

Corre, J. ;

Drzezga, A. ;

Nordberg, A. ;

Ossenkoppele, R. ;

Zetterberg, H. ;

Blennow, K. ;

Frisoni, G. B. ;

Garibotto, V. ;

Hansson, O. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (07) :2140-2156

[4] Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease [J].

Barage, Sagar H. ;

Sonawane, Kailas D. .

NEUROPEPTIDES, 2015, 52 :1-18

[5] A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease [J].

Barthelemy, Nicolas R. ;

Li, Yan ;

Joseph-Mathurin, Nelly ;

Gordon, Brian A. ;

Hassenstab, Jason ;

Benzinger, Tammie. L. S. ;

Buckles, Virginia ;

Fagan, Anne M. ;

Perrin, Richard J. ;

Goate, Alison M. ;

Morris, John C. ;

Karch, Celeste M. ;

Xiong, Chengjie ;

Allegri, Ricardo ;

Mendez, Patricio Chrem ;

Berman, Sarah B. ;

Ikeuchi, Takeshi ;

Mori, Hiroshi ;

Shimada, Hiroyuki ;

Shoji, Mikio ;

Suzuki, Kazushi ;

Noble, James ;

Farlow, Martin ;

Chhatwal, Jasmeer ;

Graff-Radford, Neill R. ;

Salloway, Stephen ;

Schofield, Peter R. ;

Masters, Colin L. ;

Martins, Ralph N. ;

O'Connor, Antoinette ;

Fox, Nick C. ;

Levin, Johannes ;

Jucker, Mathias ;

Gabelle, Audrey ;

Lehmann, Sylvain ;

Sato, Chihiro ;

Bateman, Randall J. ;

McDade, Eric ;

Allegri, Ricardo ;

Bateman, Randy ;

Bechara, Jacob ;

Benzinger, Tammie ;

Berman, Sarah ;

Bodge, Courtney ;

Brandon, Susan ;

Brooks, William ;

Buck, Jill ;

Buckles, Virginia ;

Chea, Sochenda .

NATURE MEDICINE, 2020, 26 (03) :398-+

[6] Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases [J].

Bilousova, Tina ;

Miller, Carol. A. ;

Poon, Wayne W. ;

Vinters, Harry V. ;

Corrada, Maria ;

Kawas, Claudia ;

Hayden, Eric Y. ;

Tepow, David B. ;

Glabe, Charles ;

Albay, Ricardo, III ;

Cole, Gregory M. ;

Teng, Edmond ;

Gylys, Karen H. .

AMERICAN JOURNAL OF PATHOLOGY, 2016, 186 (01) :185-198

[7] Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer's disease pathogenesis [J].

Boche, Delphine ;

Denham, Nathan ;

Holmes, Clive ;

Nicoll, James A. R. .

ACTA NEUROPATHOLOGICA, 2010, 120 (03) :369-384

[8] Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain [J].

Boutajangout, Allal ;

Ingadottir, Johanna ;

Davies, Peter ;

Sigurdsson, Einar M. .

JOURNAL OF NEUROCHEMISTRY, 2011, 118 (04) :658-667

[9] Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial [J].

Boxer, Adam L. ;

Qureshi, Irfan ;

Ahlijanian, Michael ;

Grundman, Michael ;

Golbe, Lawrence, I ;

Litvan, Irene ;

Honig, Lawrence S. ;

Tuite, Paul ;

McFarland, Nikolaus R. ;

O'Suilleabhain, Padraig ;

Xie, Tao ;

Tirucherai, Giridhar S. ;

Bechtold, Clifford ;

Bordelon, Yvette ;

Geldmacher, David S. ;

Grossman, Murray ;

Isaacson, Stuart ;

Zesiewicz, Theresa ;

Olsson, Tina ;

Muralidharan, Kumar Kandadi ;

Graham, Danielle L. ;

O'Gorman, John ;

Haeberlein, Samantha Budd ;

Dam, Tien .

LANCET NEUROLOGY, 2019, 18 (06) :549-558

[10] Human secreted tau increases amyloid-beta production [J].

Bright, Jessica ;

Hussain, Sami ;

Dang, Vu ;

Wright, Sarah ;

Cooper, Bonnie ;

Byun, Tony ;

Ramos, Carla ;

Singh, Andrew ;

Parry, Graham ;

Stagliano, Nancy ;

Griswold-Prenner, Irene .

NEUROBIOLOGY OF AGING, 2015, 36 (02) :693-709

← 1 2 3 4 5 6 7 8 →